Table 4

Association of BRAF and NRAS mutations with various clinical parameters

Clinical factorGenotypeP
BRAF mut (n = 42)NRAS mut (n = 21)Wild type (n = 8)
Gender
 Male25 (56.8%)13 (29.5%)6 (13.6%)
 Female17 (63.0%)8 (29.6%)2 (7.4%)0.776a
Age at diagnosis, yr (mean ± SD)55.3 ± 16.564.4 ± 15.954.9 ± 24.10.136b
Clinical stage at diagnosis
 I–II38 (58.5%)19 (29.2%)8 (12.3%)
 III2 (50.0%)2 (50.0%)
 IV1 (100%)0.770a
Histogenetic type
 SSMc23 (56.1%)13 (31.7%)5 (12.2%)
 NM17 (63.0%)8 (29.6%)2 (7.4%)
 LMM1 (100%)0.895a
Level of tumor invasion
 II1 (50.0%)1 (50.0%)
 III22 (75.9%)4 (13.8%)3 (10.3%)
 IV16 (51.6%)11 (35.5%)4 (12.9%)
 V2 (28.6%)5 (71.4%)0.075a
Tumor thickness, mm (mean ± SD)3.5 ± 2.64.6 ± 5.43.3 ± 2.80.518b
Ulceration
 Yes24 (64.9%)9 (24.3%)4 (10.8%)
 No17 (53.1%)12 (37.5%)3 (9.4%)0.478a
Site of first recurrence
 Regional lymph node metastasis29 (63.0%)11 (23.9%)6 (13.0%)
 Regional skin metastasis4 (30.8%)7 (53.8%)2 (15.4%)
 Distant metastasis8 (72.7%)3 (27.3%)0.138a
  • a χ2 exact test, two sided.

  • b One-way ANOVA with F-test.

  • c SSM, superficial spreading melanoma; NM, nodular melanoma; LMM, lentigo maligna melanoma.